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Abstract 
Cannabinoids have been used for many centuries to ease pain and in the past decade, the 
endocannabinoid system has been implicated in a number of pathophysiological conditions, such as 
mood and anxiety disorders, movement disorders such as Parkinson’s and Huntington’s disease, 
neuropathic pain, multiple sclerosis, spinal cord injury, atherosclerosis, myocardial infarction, 
stroke, hypertension, glaucoma, obesity, and osteoporosis. Several studies have demonstrated that 
cannabinoids also have anti-cancer activity and as cannabinoids are usually well tolerated and do 
not produce the typical toxic effects of conventional chemotherapies, there is considerable merit in 
the development of cannabinoids as potential anticancer therapies. Whilst the presence of 
psychoactive effects of cannabinoids could prevent any progress in this field, recent studies have 
shown the value of the non-psychoactive components of cannabinoids in activating apoptotic 
pathways, inducing anti-proliferative and anti-angiogenic effects. The aforementioned effects are 
suggested to be through pathways such as ERK, Akt, mitogen-activated protein kinase (MAPK) 
pathways, phosphoinositide 3-kinase (PI3K) pathways and hypoxia inducible factor 1 (HIF1), all of 
which are important contributors to the hallmarks of cancer. Many important questions still remain 
unanswered or are poorly addressed thus necessitating further research at basic pre-clinical and 
clinical levels. In this review, we address these issues with a view to identifying the key challenges 
that future research needs to address. 
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Abbreviations:  
ABCC1, ATP-binding cassette (ABC) transporter  
AC, adenylyl cyclase  
AEA, anandamide 
AKt, protein kinase B 
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AM251, a CB1 receptor antagonist 
AM630, a CB2 receptor antagonist  
AMPK, 5’-adenosine monophosphate-activated protein kinase  
ATF-4, activating transcription factor-4 
AR, androgen receptors  
CBD, cannabidiol 
CB1IR, CB1 receptor immunoreactivity 
Cdk, cyclin-dependant kinase  
Chk 1, cell cycle checkpoint  
COX2, cyclooxygenase-2 
CXCR4, chemokine receptor 4 
CXCL12, a chemokine protein encoded by the CXCL12 gene   
Δ9-THC, ∆9-tetrahydrocannabinol 
EGFR, epidermal growth factor receptor 
ER, Oestrogen 
ERK, extracellular signal-regulated kinase 
FAAH, fatty acid amide hydrolase  
FAK, focal adhesion kinase 
GBM, glioblastoma multiform 
Gi/o, a subunit of G protein  
GTPγS, guanosine 5'-O-[gamma-thio] triphosphate 
HER2, human epidermal growth factor receptor 2  
HIF-α, hypoxia-inducible factor  
HU-210, highly potent cannabinoid receptor agonist, 96aR0-trans-3-91, 1-Dimethylheptyl)- 
6a, 7, 10, 10a-tetrahydro-1-hydroxy-6, 6-dimethyl-6H-dibenzo [b,d]pyran-9-methanol  
ICAM, intracellular adhesion molecule  
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JWH-015, a selective CB2 agonist, 2-Methyl-1-propyl-1H-indol-3-yl)-1-naphthalenylmethanone  
JWH-133, a potent selective CB2 agonist, (6aR, 10aR)-3-(1,1-dimethylbutyl)-6a,7,10,10a- 
Tetrahydro-6, 6, 9-trimethyl-6H- dibenzo [b,d]pyran MAPK, mitogen activated protein kinase 
LAK, lymphokine-activated killer  
LPI, lysophosphatidylinositol  
MAGL, monoglycerol lipase  
MMP-2, matrix metallopeptidase 2 
MMP-9, matrix metallopeptidase 9 
MRP1, Multidrug resistance-related protein 1 
mTOR, mammalian target of rapamycin 
NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells  
NGF, nerve growth factor 
PD98059, p42/44 inhibitor, 2-(2-Amino-3-methoxyphenyl)-4/h-1-benzopyran-4-one 
PGE2 , prostaglandine E-2 
PI3K, phosphoinositide 3-kinase 
PKA, protein kinase A 
PCNA, proliferating cell nuclear antigen  
PPARs, peroxisome proliferator-activated receptors 
PR, progesterone 
PRLr, prolactin receptor 
PSA, prostate specific antigen 
PyMT, polyoma middle T oncoprotein 
RAF-1, a proto-oncogene, serine/threonine kinase  
ROS, reactive oxygen species  
RXRα, retinoid X receptor  
SB203580, a p38/MAPK inhibitor, 4-[5-(4-Fluorophenyl)-2-[4-(methylsulphonyl) phenyl]-1H- 
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imidazol-4-yl] pyridine 
SC58236, COX-2-specific inhibitor, 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1- 
yl]benzenesulfonamide 
siRNA, small interfering RNA  
SR141716, Rimonabant, a selective CB1 receptor antagonist or an inverse agonist 
Src gene, a family of proto-oncogenic tyrosine kinases 
Th1, a type of T helper cells  
Th2, a type of T helper cells 
TIMP-1, tissue inhibitor of matrix metalloproteinases-1 
TrK A, tropomyosin receptor kinase A 
TRPM8, transient receptor potential channels of melastatin-type 8  
TRPVA1, transient receptor potential A1 
TRPV1, transient receptor potential vanilloid 1 
TRB3, tribbles homolog that inhibits Akt/PKB activation 
2-AG, 2-arachidonoyl glycerol 
VEGF, vascular endothelial growth factor 
WIN 55,212-2, a CB1 and CB2 receptor agonist [(R0-(+)-[2, 3-Dihydro-5-methyl-3-(4- 
morpholinylmethyl) pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphtalenylmethanoneesylate] 
 
1. Introduction 
It is known that cannabinoids, the active components of Cannabis sativa, act by mimicking the 
endogenous substances (the endocannabinoids anandamide and 2-arachidonoylglycerol (2-AG)) by 
activating specific cell-surface cannabinoid receptors (Devane et al., 1992). Currently, the 
cannabinoid receptor ligands are generally divided into three main categories known as 
phytocannabinoids, endogenous cannabinoids and synthetic cannabinoids (figure 1). After the 
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clarification of the chemical structure of (-)-9-tetrahydrocannabinol (Δ9-THC) which is the primary 
psychoactive component of the cannabis plant (Gaoni, 1964a; Gaoni, 1964b), other chemically 
related terpenophenolic compounds were identified in Cannabis sativa, including cannabichromene 
(CBC) (Gaoni, 1966) and cannabigerol (CBG) (Gaoni, 1964c). Although the pharmacology of most 
of the cannabinoids is unknown, Δ9-THC is the most widely studied owing to its high potency and 
abundance in cannabis (Pertwee et al., 2010). Among the herbal cannabinoids, other relevant plant-
derived cannabinoids include Δ8-THC, which is almost as active as Δ9-THC but less abundant and 
cannabinol (CBN), which is produced in large amounts but is a weak cannabomimetic agent. 
Cannabidiol (CBD), CBG and CBC are devoid of psychoactive potential. The chemical structures 
of some cannabinoids are shown in figure 1. 
So far, two cannabinoid-specific receptors  CB1 and CB2  have been cloned and characterized 
from mammalian tissues (Howlett et al., 2002). Mouse CB1 receptor and CB2 receptor  share 66% 
overall homology and 78% in the transmembrane region (Shire et al., 1996). Human CB1 receptor 
and CB2 receptor share an overall homology of 44%, and 68% in the transmembrane region 
respectively (Munro et al., 1993). Homology (96%) has been reported between human and mouse 
CB1 receptor (Chakrabarti et al., 1995), whilst human and mouse CB2 receptors share 82% 
homology (Shire et al., 1996). Many central and peripheral effects have been associated with the 
activation of CB1-receptors (Matsuda et al., 1990; Munro et al., 1993; Pertwee, 2006; Pertwee et al., 
2010). The CB2 receptor, originally thought of as being exclusively present in the immune system, 
is highly expressed in B and T lymphocytes, macrophages and in tissues such as the spleen, tonsils 
and lymph nodes (Herkenham et al., 1991; Howlett et al., 2002; Porter et al., 2001; Pertwee et al., 
2010). Recently CB2 receptors have been shown to be also located in the brain stem (Van Sickle et 
al., 2005). Further studies using CB1 knockout mice demonstrated that CB1 receptors are involved 
in a variety of different behavioural disorders such as depression, anxiety, feeding and cognition as 
well as pain at the peripheral, spinal and supraspinal levels (Valverde et al., 2005). Such studies 
 7
using CB1 knockout mice also revealed the interactions between different systems such as opioids, 
gamma aminobutyric acid (GABA) and cholecystokinin (CCK) via CB1 receptors (Valverde et al., 
2005).  CB2 knockout mice have also been developed and revealed/confirmed the involvement of 
CB2 receptors in a variety of different systems such as immune system, inflammation, apoptosis, 
chemotaxis, bone loss, liver disorder, pain and atherosclerosis (Buckley, 2008). 
Both CB1 and CB2 receptors are metabotropic and belong to the G-protein coupled receptor 
family (Howlett et al., 2002). Activation of CB1 and CB2 receptors stimulates cellular signalling via 
alpha subunit of G protein (Gi/o), leading to inhibition of adenylate cyclase and the subsequent 
activation of many other pathways such as mitogen-activated protein kinase (MAPK) pathways, 
phosphoinositide 3-kinase (PI3K) pathways, modulation of ion channels (through CB1 receptors), 
protein kinase B (Akt), ceramide signalling pathways in tumour cells and modulation of  
cyclooxygenase-2 (COX-2) signalling pathway (Demuth et al., 2006; Galve-Roperh et al., 2000; 
Glass et al., 1999; Guzman et al., 2001; Qamri et al., 2009).  
There is also pharmacological evidence that non-CB1 and non-CB2 receptors mediate the 
actions of cannabinoids located in the brain (Breivogel et al., 2001; Di Marzo et al., 2000). The  
hypothesis that putative CB3 or non-CB1/CB2 receptor exist is supported by the fact that some of the 
anandamide (AEA)-mediated effects were neither inhibited by selective CB antagonists nor fully 
abolished in knockout mice lacking CB1 receptors (De Petrocellis et al., 2010). Recent advances 
suggest, at least for AEA, that the transient receptor potential vanilloid 1 receptor (TRPV1) channel 
may be considered as the “third” receptor involved in endocannabinoid signaling (Di Marzo et al., 
2001; Ross, 2003). For example, it has been shown that the endocannabinoids exert their apoptotic 
effect by binding to TRPV1, a non-selective cation channel targeted by capsaicin, the active 
component of hot chilli peppers (Smart & Jerman, 2000). However, the precise role of this receptor 
in cannabinoid signalling is still unclear and this uncertainty extends into the cancer field where its 
potential role in cancer biology (proliferation and migration of cancer cells) and cancer 
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pharmacology  (resistance to chemotherapeutic agents) needs further investigation (Lehen'kyi et al., 
2011; Liberati et al., 2013). Evidence also exists supporting a role for peroxisome proliferator-
activated receptors (PPARs) in the actions of cannabinoids (Sun et al., 2007). More recent studies 
have provided evidence for the interaction of cannabinoids with the orphan receptors such as G 
protein receptor 55 (GPR55) (Andradas et al., 2011; Pineiro et al., 2011). Thus in addition to CB1 
and CB2 receptors other targets might be involved in mediating an effect to cannabinoids and 
endocannabinoids. 
The potential of cannabinoids to alleviate pain has been recognized for many centuries. The 
antinociceptive actions are mediated via both the CB1 and CB2 receptors (Pacher et al., 2006). This 
does not negate a role for other receptors such as TRPV1, transient receptor potential cation channel 
A1(TRPA1), orphan GPCR (i.e. GPR55) or PPAR-γ (Maione et al., 2006; Maione et al., 2013; 
Perez-Gomez et al., 2013; Moreno et al., 2014). For a long time, the development of cannabinoids 
as anticancer agents has been restricted to two therapeutic avenues (antiemetic and analgesic). They 
have therefore been evaluated in terms of palliative care as cannabinoids can play an important role 
in the relief of pain, nausea, vomiting, and stimulation of appetite in cancer patients. However, the 
involvement of CB receptors in pain and their use in the palliative care in cancer patients are not the 
focus of this review. In the present review, the aim is to focus on the anti-tumour effects of 
cannabinoids, identify potential mechanisms by which cannabinoids induce anti-tumour effects and 
discuss the potential and challenges for the future development of this class of compound.   
 
2. Anti-tumour effects of cannabinoids 
Whilst cannabinoids exert palliative effects in cancer patients by preventing nausea, 
vomiting and pain and by stimulating appetite, they have also been shown to inhibit the growth of 
tumour cells in culture and animal models by modulating key cell-signalling pathways. In 1975, 
Munson and collaborators were the first to report the anti-proliferative properties of cannabis 
compounds (Munson et al., 1975). They showed that Δ9-THC inhibits lung-adenocarcinoma cell 
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growth in vitro and after oral administration in mice. It was not until the late 1990s however that 
further studies on the anti-cancer effects of cannabinoids were carried out. Several plant-derived 
(for example, Δ9-THC and CBD), synthetic (for example, WIN-55, 212-2 and HU-210) and 
endogenous cannabinoids (for example, AEA and 2-AG) are now known to exert anti-proliferative 
actions on a wide range of tumour cells in vitro (Guzman et al., 2002). The involvement of CB1 
and/or CB2 receptors in the anti-tumour effects of cannabinoids has been shown by various 
biochemical and pharmacological approaches, in particular by determining cannabinoid-receptor 
expression and by using selective cannabinoid-receptor agonists and antagonists (Guzman et al., 
2003; Sarfaraz et al., 2008; Pisanti et al., 2013 ;Velasco et al., 2012). Such studies have shown that 
cannabinoids can prevent proliferation, metastasis, angiogenesis and exert pro-apoptotic effects in a 
variety of cancer cell types such as lung, breast, prostate, skin, intestine, glioma, lymphoma, 
pancreas and uterus (Blazquez et al., 2006; Carracedo et al., 2006b; Casanova et al., 2003; Cianchi 
et al., 2008; Galve-Roperh et al., 2000; Guzman, 2003; Pacher et al., 2006; Sanchez et al., 2001a; 
Sanchez et al., 2001b). Silencing CB2 receptors with specific small interfering RNA (siRNA) in 
prostate cancer cells (PC-3) revealed the involvement of CB2 receptors in the growth inhibition of 
prostate cancer cells (Olea-Herrero et al., 2009) via stimulation of autophagy. Cannabinoid-induced 
AMPK activation of autophagy was also confirmed in vivo (Vara et al., 2011). The over expression 
of cannabinoid receptors and elevated endocannabinoid levels have also been reported in a variety 
of different cancer types such as prostate, skin, hepatocellular carcinoma, colon, endometrial 
sarcoma, glioblastoma multiforme (GBM), meningioma and pituitary adenoma (see table 1) 
(Blazquez et al., 2006; Xu et al., 2006; Pisanti et al., 2013). CB1 receptors are also up-regulated in 
Hodgkin lymphoma cells and also in chemically induced hepatocarcinoma (Benz et al., 2013; 
Mukhopadhyay et al., 2015). Also the expression of CB1 and CB2 receptors was found to increase 
in mantel cell lymphoma and fatty acid amide hydrolase (FAAH) expression was reduced when 
compared to non-malignant B-cells (Islam et al., 2003; Ek et al., 2002; Wasik et al., 2014). It has 
also been shown in both the mouse model of metastatic melanoma and in humans that the 
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circulating endocannabinoid levels have been associated with an increase in disease progression 
(Sailler et al., 2014). Indeed many reports have shown that an increase in the level of 
endocannabinoids and their receptors correlates with tumour aggressiveness (Malfitano et al., 2011) 
and that cannabinoids can inhibit the growth of xenograft tumours (Blazquez et al., 2006; Carracedo 
et al., 2006b; Sanchez et al., 2001a).  
In neoplastic cells cannabinoids have also been shown to inhibit angiogenesis and directly 
initiate apoptosis or cell cycle arrest  (Blazquez et al., 2006; Carracedo et al., 2006b; Sanchez et al., 
2001a). Other studies have shown the ability of cannabinoids to affect cellular signalling pathway/s 
essential for cell survival and growth (Bifulco et al., 2008; Kogan, 2005). Some studies have also 
demonstrated and suggested the involvement of autophagy in the mechanism of cannabinoid-
induced cytotoxicity (Armstrong et al. 2015; Vara et al., 2011; McAllister et al., 2015). 
Cannabinoids have also been reported to inhibit nerve growth factor (NGF)-induced proliferation of 
PC-3 cells (Melck et al., 2000) through interaction with CB1 receptors and synthetic 
endocannabinoid-vanilloid hybrids via stimulation of TRPV1 channels. However, other studies 
demonstrate that cannabinoid-induced anti-tumour activity was only marginally dependent upon the 
interaction between cannabinoid and TRPV1 receptors (Massi et al., 2004; Torres et al., 2011; 
Vaccani et al., 2005). On the other hand, cannabinoids have also been shown to actively induce 
apoptosis in these cells via a CB1 receptor-independent mechanism as the Δ9-THC-induced 
apoptosis was not reversed by the CB1 receptor antagonist, SR141716 (Ruiz et al., 1999).  
The effects of cannabinoids in modulating cell cycle and signalling pathways are diverse 
(Figure 2) and may depend on the type of tumour cells. Whilst there is evidence showing that some 
cannabinoids induce anti-proliferative effect on tumour cells in vitro (Hart et al., 2004; White et al., 
1976; Velasco et al., 2015), there is evidence to suggest that the effects may depend upon the 
disease context with differential effects seen in different tumour types. The subsequent sections 
focus specifically on the evidence of cannabinoid induced anti-tumour effects in specific cancer 
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types with the aim of exploring the mechanism of action of non-psychoactive components of 
cannabinoids in a disease specific context.  
 
3. Cannabinoids and breast cancer  
The first report on the antineoplastic property of cannabinoids in breast cancer are in the late 
1990s, when it was shown that pre-treatment with the endocannabinoid anandamide inhibited 
prolactine- and nerve growth factor-induced proliferation of two hormone-sensitive, oestrogen and 
progesterone (ER+/PR+) breast cancer cell lines (EFM-19 and MCF-7 cell lines). In this case, 
treatment reduced the levels of prolactin receptor (PRLr) and nerve growth factor receptors via CB1 
receptor activation. Thus, the inhibition of adenylyl cyclase activity that in turn induced prolonged 
activation/stimulation of the RAF1-MEK-ERK cascade, leads to a down-regulation of the PRL 
receptor and levels of TrkA NGF receptors (De Petrocellis et al., 1998; Melck et al., 2000; Melck et 
al., 1999). Of interest, other studies showed that in both MCF-7 cells and tamoxifen-resistant MCF-
7 (TAMR-MCF-7) tumour cells, anti-angiogenesis effects exerted by novel synthetic 
hexahydrocannabinol analogues was through the suppression of VEGF (Thapa et al., 2011). It 
should be noted that both MCF-7 and TAMR-MCF-7 cells have shown a strong association 
between enhanced VEGF production and more aggressive phenotype (Kim et al., 2008; Kim et al., 
2009). The anti-angiogenesis activity afforded by the novel synthetic cannabinoids were shown to 
be independent of CB1 and CB2 receptor activity and through an inhibition of NF-κB transcriptional 
activity which in turn plays an important role in VEGF regulation and angiogenesis (Thapa et al., 
2011). Further studies demonstrated that the proliferation of EVSA-T, a hormone-sensitive (ER-
/PR+) breast cancer cell line, was also inhibited by TCH via CB2 receptor activation. This caused 
the activation of the transcription factor JunD, the up-regulation of gene expression and subsequent 
translocation of protein to the nuclear compartment (Caffarel et al., 2008). Thus, it seems that 
cannabinoids do activate many cell-specific pathways, however not all pathways are simultaneously 
stimulated (Figure 3).  In addition to their anti-mitogenic property, cannabinoids have been also 
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shown to play a role in hormone-sensitive breast cancer cell migration and invasion. Specifically, 
CB2 has recently been found to modulate breast tumour growth and metastasis by inhibiting 
signalling of the chemokine receptor CXCR4 and its ligand CXCL12 in both in MCF7 
overexpressing CXCR4 and NT2.5 injected immune-competent syngenic FVB mice (Nasser et al., 
2011).  However, other studies showed that Δ9-THC enhanced breast cancer growth and metastasis 
although specifically in cells expressing low levels of cannabinoid receptors (i.e. mouse mammary 
carcinoma 4T1 cells) by suppressing the antitumor immune response (McKallip et al., 2005). Such 
studies showed that exposure to Δ9-THC led to an increase in the level of cytokines such as IL-4 
and IL-10, suggesting that Δ9-THC exposure may specifically suppress the cell-mediated Th1 
response by enhancing Th2-associated cytokines (McKallip et al., 2005). Among the hormone-
sensitive histopathological subtypes, it should be mentioned that in breast tumours that express the 
tyrosine kinase receptor HER2, cannabinoids have been shown to be very effective. In fact, in 
addition to the correlation between tumour aggressiveness and CB2 receptor expression in breast 
cancer, a significant correlation between CB2 receptor and ErbB2 has been recently demonstrated 
(Caffarel et al., 2010). In particular, this study showed that the selective agonist JWH-133 was as 
effective as Δ9-THC (a CB1/CB2-mixed agonist) in reducing tumour growth and progression 
through inhibition of the pro-tumorigenic kinase Akt pathway. Moreover, in vivo studies reported 
that Δ9-THC was efficacious in reducing tumour growth, tumour number, and the amount/severity 
of lung metastases in MMTV-neu mice (Caffarel et al., 2010).  
Another group of clinically important breast tumours are triple-negative tumours. These 
tumours are characterized by the total lack of expression in ER, PR or HER2. Numerous pieces of 
evidence both in vitro and in vivo, demonstrate that cannabinoids (acting through a plethora of 
different mechanisms) can be considered as promising candidates for the treatment of ER-/PR-
/HER2- breast cancer. The metabolically stable anandamide analogue (Met-F-AEA), significantly 
affected adhesion and migration of both the highly invasive human breast carcinoma cell line 
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(MDA-MB-231) and murine breast cancer cell line (TSA-E1) by reducing FAK tyrosine 
phosphorylation/activation and Src phosphorylation via CB1 receptor (Grimaldi et al., 2006). 
Interestingly, the same group reported that pre-treatment with SR141716 could also inhibit tumour 
growth or induce apoptosis possibly through an inhibition of ERK1/2 signalling in lipid rafts and 
caveolae (Sarnataro et al., 2006). Both are highly implicated in tumour growth and metastasis in 
breast cancer (Sloan et al., 2004; Williams et al., 2004). Later studies reported an over- expression 
of cannabinoid  receptors in primary human breast tumours compared with normal breast tissues, as 
well as in breast cancer cell lines MDA-MB231 and MDA-MB468 (Qamri et al., 2009). Such 
studies have shown that stimulation of both CB1 and CB2 receptor by their agonists, WIN-55,212-2 
and JWH-133, respectively inhibited cell proliferation and migration in breast cell lines. The results 
were in line with in vivo findings where in mammary gland tumours in the polyoma middle T onco-
protein (PyMT) transgenic mice model, a genetically engineered model of triple negative breast 
cancer, WIN-55,212-2 or JWH-133 showed a reduction in tumour growth and lung metastasis. 
Inhibition induced by the agonists was sensitive to antagonism by CB1 and CB2 antagonists AM 
251 and SR144528, suggesting involvement of CB1 and CB2 receptors.  
In terms of signal transduction pathways, cyclooxygenase-2 and prostaglandin E2, via the 
regulation of GTPases and transcription factors, have been implicated in the action of cannabinoids 
on breast cancer growth and metastasis (Qamri et al., 2009). Such studies also reported a significant 
reduction in angiogenesis (CD31 staining) and attenuation of proliferation (Ki67 staining).  A 
reduction in the level of Cdc42 activity and nuclear expression of transcription factors c-Jun and c-
Fos in MDA-MB231 cells were also reported (Qamri et al., 2009).  
The involvement of CB1 as well as TRPV1 receptors on the invasiveness of MDA-MB-231 
cells has been recently discussed. Selective agonists were shown to reduce cell invasion and 
accordingly MMP-2 expression (Farsandaj et al., 2012). In addition, a down-regulation of  vascular 
endothelial growth factor and concomitantly over-expression of COX-2 were also reported 
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(Farsandaj et al., 2012). In addition, phytocannabinoids were shown to be as effective as synthetic 
compounds (Ligresti et al., 2006). Particularly, CBD was reported to be effective at inhibiting cell 
proliferation of both hormone-sensitive (MCF-7 ) and hormone-negative (MDA-MB-231) cells 
showing a combination of cell type dependent mechanisms of action which include either direct or 
indirect activation of CB2 and TRPV1 receptors and induction of oxidative stress, all contributing to 
induce apoptosis. The efficacy of CBD was also corroborated with in vivo data in athymic mice 
injected with human MDA-MB-231 breast carcinoma cells (Ligresti et al., 2006). Indeed, it was 
also shown that in MDA-MB231, a human breast cell line, CBD induced endoplasmic reticulum 
stress, inhibition of AKT/mTOR pathway, and up-regulation of autophagy-mediated cell death 
(Shrivastava et al., 2011). Recent studies indicated an anticancer activity induced by a 
quinone/cannabinoid derivative through the activation of CB2 receptors and oxidative stress 
mechanism to induce apoptosis in triple-negative breast cancer, a highly aggressive type of breast 
cancer (Morales et al., 2015). Other recent studies indicated that CBD significantly inhibits 
epidermal growth factor (EGF)-induced proliferation and chemotaxis of breast cancer cells. In 
addition, it was shown that CBD inhibits EGF-induced activation of EGFR, ERK, AKT and NF-kB 
signaling pathways as well as MMP2 and MMP9 secretion (Elbaz et al., 2015). CBD also inhibited 
tumour growth and metastasis in different mouse model systems. Analysis of molecular 
mechanisms revealed that CBD significantly inhibits the recruitment of tumour-associated 
macrophages in primary tumour stroma and secondary lung metastases (Elbaz et al., 2015). Figure 3 
summarizes the important pathways in cannabinoid induced cytotoxicity. 
4. Cannabinoids and brain cancer  
Both CB1 and CB2 receptors have been identified in the CNS (Ameri, 1999; Benito et al., 
2007; Herkenham et al., 1991; Nunez et al., 2004; Skaper et al., 1996). High density of CB1 
receptors has been reported in different areas of the brain such as in the cortex, cerebellum and 
hippocampus (Herkenham et al., 1991; Hoffman et al., 2010; Sullivan, 2000; Tsou et al., 1998). The 
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CB1 receptor protein is mainly localized in astroglial cells and neurones whereas CB2 receptors are 
located on microglial cells (Held-Feindt et al., 2006; Stella, 2004) with possible neuroprotective  
activity (Cabral et al., 2008; Kreitzer et al., 2009) and in some benign paediatric astrocyte tumours 
(Ellert-Miklaszewska et al., 2007). The anti-tumour effect of cannabinoids on gliomas, glioblastoma 
multiforme or astrocytoma that are the most frequent class of malignant primary brain tumours, will 
be discussed below. Although the downstream events by which cannabinoids exert their action are 
not completely elucidated, it can be generally assumed that they act at least through two 
mechanisms: induction of apoptosis of tumour cells and/or inhibition of tumour angiogenesis and 
migration.  
The anti-tumour action of two cannabinoid receptor agonists, Δ9-THC and WIN-55,212-2, 
was shown to be mediated by an increase in the level of ceramide leading to the activation of 
extracellular signal-regulated kinase (ERK1/2) in C6 glioma cells (Galve-Roperh et al., 2000; 
Guzman, 2003). In addition, positive actions of CP 55-940 include a selective induction of cell 
death in a hybrid cell line of neuroblastoma plus glioma where consistent anti-proliferative effects 
were observed (Tomiyama and Funada, 2011). It was of interest to note that  CP 55-940 had a 
selective and differential action on C6 compared to the U373 astrocytoma cell lines. Results showed 
that C6 cells were dying faster than the U373 cells mainly via necrotic mechanisms after being 
exposed to CP 55-940, whilst U373 cells underwent early apoptosis and displayed a more defined 
laddering pattern (Ortega et al., 2015). This illustrates that the effects of cannabinoids on cancer cell 
lines in vitro is context specific. 
Other studies (Ellert-Miklaszewska et al., 2005) also showed a down regulation of 
phosphoinositide 3-kinase (PI3K), protein kinase B (Akt), and ERK signalling pathways, and 
activated pro-apoptotic function of Bad protein, which lead to induction of apoptosis. In similar 
experiments using the CB2 receptor agonist JWH-133, apoptosis was induced in glioma cells via 
enhanced ceramide synthesis de novo (Sanchez et al., 2001a; Sarfaraz et al., 2008). However, in 
addition to ceramide pathway, other pathways such as stress-regulated protein p8 which leads to the 
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activation of activating transcription factor-4 (ATF-4) and cell death–inducible kinase (TRB3) were 
shown as mechanism/s of the anti-tumour action of cannabinoids (Carracedo et al., 2006a). Other 
studies have demonstrated that CBD, via receptor-independent manner, triggers apoptosis of human 
glioma cells by a cellular mechanism that involves an early production of reactive oxygen species 
(ROS), depletion of glutathione (GSH), and concomitant activation of caspase cascade with no 
effect in non-transformed cells (Massi et al., 2006). Moreover, the same group, reported that CBD 
can inhibit proliferation and invasion of different glioma cell lines through a multi-target 
mechanism affecting the most relevant pro-tumour ERK and PI3K/Akt signalling pathways, as well 
as the expression of the transcription factor HIF-1α which was down following a treatment with 
CBD. Such experiments were conducted under ‘pseudo-hypoxic conditions’ (Solinas et al., 2013). 
This raises the possibility that these compounds could have activity against hypoxic cells but to the 
best of our knowledge, no studies of this nature have been conducted. 
Remarkably, the cannabinoid-mediated anti-proliferative action appears to be selective for 
brain-tumour cells as the survival of normal brain cells astrocytes (Gomez Del Pulgar et al., 2002), 
oligodendrocytes (Molina-Holgado et al., 2002) and neurons (Mechoulam et al., 2002) are 
unaffected or even favoured by cannabinoid challenge. Accordingly, a pilot phase I clinical trial, in 
a cohort of recurrent glioblastoma multiforme tumour patients expressing cannabinoid receptors 
reported an anti-proliferative action for Δ9-THC on tumour cells with an acceptable safety profile 
(Guzman et al., 2006). Further phase 1b/2a clinical trials are underway and await publication.  
 
Based on these findings, other studies evaluated the expression of cannabinoid receptors in 
surgical material of solid astrocytomas, gliomas and glioma cell lines. Whilst CB1 expression was 
slightly increased in astrocytomas and gliomas, the CB2 expression was similar in both tumour and 
normal brain tissue. The authors found, in accordance with this receptor subtype expression in situ, 
that agonists selective for CB1 or active on both subtypes reduced elevated cyclic AMP levels and 
cell proliferation, but failed to induce apoptosis in glioma cells in vitro (Held-Feindt et al., 2006). 
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Further experiments described opposite changes in CB1 and CB2 receptor protein expression in 
human gliomas (Lopez de Jesus et al., 2010). The reduction in the level of CB1 receptor expression 
or mRNA in glial tumours is suggested to be related to the neuronal loss (Canoll & Goldman, 
2008). The reduction in CB1 receptor expression was in line with a reduction in the WIN 55,212-2 
stimulated [35S]GTPγS binding to glioblastoma multiforme membranes. This suggested a reduction 
in the number of available receptors in the glioblastomas. Similar observations were reported in the 
brain of aged rats (Romero et al., 1998). It should be noted that similar reductions were also 
observed in neurodegenerative diseases such as Alzheimer's, Parkinson's and Huntington's diseases, 
and also in normal aging (Glass et al., 1993; Hurley et al., 2003; Richfield et al., 1994; Westlake et 
al., 1994). In particular the up-regulation of CB2 receptors has also been reported in other disorders 
such as Alzheimer's, Huntington's diseases, encephalitis and multiple sclerosis (Benito et al., 2007; 
Benito et al., 2003; Fernandez-Ruiz et al., 2007). It is suggested that reduction in the level of CB1 
receptors occurs as a result of neuronal loss, possibly simultaneous to the enhanced brain gliosis 
that appears with normal aging. In addition to an up-regulation of CB2 receptors in malignant 
tumours, the level of anandamide was reported to increase in glioblastomas (Petersen et al., 2005). 
It can then be suggested that the endogenous anandamide will bind to CB2 receptors to mediate an 
anti-tumour activity. This is in line with studies by Sanchez et al in 2001 who reported a 
considerable regression of malignant glioma cells by the local administration of a CB2 selective 
agonist (Sanchez et al., 2001a). In such studies administration of JWH-133 to an 
immunocompromised mice model, Rag-2 -/- mice inoculated with rat glioma C6-cells caused a 71% 
reduction in the tumour growth as compared to the control group and was found to be prevented by 
co-administration of the CB2 receptor antagonist, SR144528 but not the CB1 receptor antagonist, 
SR141716. Further experiments by the same group indicated that the anti-tumour effects induced by 
the activation of CB2 receptors by JWH-133 initiated apoptosis via ceramide synthesis and ERK1/2 
activation (Sanchez et al., 2001a). In later studies by Blazquez and colleagues in 2003 using the 
same mouse model, intra-tumour administration of JWH-133 showed a significant reduction in 
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mRNA expression of the pro-angiogenic factors, vascular endothelial growth factor and 
angiopoietin 2 (Blazquez et al., 2003). Additional data to support the importance of CB2 receptors 
in glioblastoma came from studies that showed an increase in the level of CB2 receptors in the 
endothelial cells of human glioblastoma vessels (Schley et al., 2009). Whilst the mechanism of 
action of CB agonists against glioblastoma is still not fully understood, it has been shown in the rat 
C6 glioma cells that the high affinity glycine transporter (GLYT1) has been attenuated via protein 
kinase C alpha (PKC-α) (Morioka et al., 2008).  Attenuation of GLYT1 would increase the 
inhibitory action of glycine transmitter in the synapse. Other studies showed that PKC inhibitors 
could impair the CB effects in neuroblastoma cells (Rubovitch et al., 2004). The above data suggest 
the involvement of downstream PKC and GLYT1 regulation in mediating an anti-glioblastoma 
activity by cannabinoids. Thus, the accumulated data suggest that the anti-tumour activity of 
cannabinoids could be mediated via ERK1/2, AKt and/or PI3K pathways as well as PKC and 
glycine transporters. The change in the levels of cannabinoid receptor expression and the levels of 
endocannabinoids depend on the stages of cancer. For example, the levels of CB2 receptors and 
anandamide increase in advanced tumours.  
 
5. Cannabinoid and lung cancer 
The first evidence of the antineoplastic activity of cannabinoids against lung cancer dates 
back to 1975 when Munson et al demonstrated a dose-dependent retardation in tumour growth in 
the Lewis lung adenocarcinoma animal model (Munson et al., 1975). Later on, further studies were 
carried out in order to elucidate the possible mechanism of action(s) of this class of molecule 
although controversial evidence about the anti-tumour action of cannabinoids were reported for this 
particular type of cancer. In fact, it has been reported that Δ9-THC suppresses the host immune 
reactivity against lung cancer and that the augmentation of tumour growth acts through inhibition of 
anti-tumour immunity by a CB2 receptor-mediated, cytokine-dependent pathway (Zhu et al., 2000). 
Δ9-THC, although without the modulation of EGFR expression or FAK phosphorylation previously 
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reported by others (Hart et al., 2004), has been also shown to attenuate the EGF-induced migration 
and invasion of epidermal growth factor receptor-overexpressing lung cancers, which are often 
highly aggressive and resistant to chemotherapy (Preet et al., 2008). Furthermore, in in vivo 
experiments, administration of Δ9-THC suppressed metastasis and subcutaneous tumour growth in 
severe combined immunodeficient mice (Preet et al., 2008). The anti-invasive effect of 
cannabinoids has also been reported (Ramer et al., 2008 and 2010). In these studies, a cannabinoid 
receptor and TRPV1-triggered expression of tissue inhibitor of matrix metalloproteinases-1 (TIMP-
1) was identified as an important mediator of the anti-invasive action of cannabidiol. Impaired 
invasion driven by CBD links the cannabinoid and TRPV1 receptors to the activation of MAPK 
pathways and subsequent TIMP-1 induction. Additionally and in line with its in vitro anti-invasive 
action, in vivo studies in thymic-aplastic  nude mice revealed a significant inhibition of A549 lung 
metastasis in cannabidiol-treated animals as compared to vehicle-treated controls (Ramer et al., 
2008 and 2010). 
   The expression of CB1 and CB2 receptors has been reported in non-small cell lung cancer 
(NSCLC) patients and also the NSCLC cell lines, A549 and SW-1573 (Preet et al., 2011). Pre-
treatment of A549 and SW-1573 cells with WIN 55,212-2 and JWH-015 reduced chemotaxis and 
chemo-invasion as well as migration and these were sensitive to blockade by the CB1 and CB2 
receptor antagonists, AM251 and AM630 respectively. Furthermore both agonists revealed a 
reduction in tumour growth in vitro, inhibited in vivo tumour growth and lung metastasis that again 
were sensitive to antagonism of CB1 and CB2 receptors (Preet et al., 2011). Mechanistic studies 
revealed an inhibition of phosphorylation of Akt and MMP-9 expression/activity upon exposure to 
the CB1 and CB2 receptor agonists in NSCLC (Preet et al., 2011). On the other hand, the 
involvement of cannabinoid receptor is not the only mechanism through which cannabinoids exhibit 
their anti-tumor proprieties. In fact, as demonstrated by Gardner et al, these molecules can exert 
some of their biological effects via modulation of prostaglandin production. This study has shown 
that administration of methanandamide at 5.0 mg kg-1 in murine lung cancer could increase the rate 
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of tumour growth (both in vitro and in vivo). Such studies also showed an increase in the level of 
prostaglandin (PG) E2 and COX-2 which were sensitive to blockade by the COX-2-specific 
inhibitor, SC58236, the p38/MAPK inhibitor, SB203528, and the p42/44 inhibitor, PD98059 but 
not to CB1 and CB2 receptor antagonists. The results confirmed an up-regulation of COX-2 which 
was independent of cannabinoid receptor activation (Gardner et al., 2003). Recently studies have 
shown an up-regulation of COX-2 induced by CBD in two different lung cancer cell lines (A549, 
H460) and primary cells from a patient with lung cancer (Ramer et al., 2013). Such studies showed 
a pro-apoptotic and tumour-regressive action by CBD through an initial up-regulation of COX-2 
and PPAR-γ and a subsequent nuclear translocation of PPAR-γ by COX-2-dependent 
prostaglandins, PGD2 (Ramer et al., 2013). Such studies also indicated that incubation of the cells 
with PGD2 but not PGE2 was associated with a concentration-dependent loss of cell viability. This 
highlighted how different cannabinoids could induce differential effects, which are CB1 and CB2 
receptor –independent pathways and also dependent on the type of PG being produced.  
In further recent studies, it was demonstrated that cannabinoids induced up-regulation of 
intercellular adhesion molecule 1 (ICAM-1) on lung cancer cells to be responsible for increased 
cancer cell lysis by lymphokine-activated killer (LAK) cells (Haustein et al., 2014).  This recent 
study suggested a new mechanism for anti-tumour activity of cannabinoids. Further experiments by 
Ramer et al also indicated that cannabinoids induce anti-angiogenic effect in endothelial cells via 
the release of TIMP-1 from lung cancer cells (Ramer et al., 2014).  
Thus, the likely pathways involved in mediating anti-tumour activity induced by 
cannabinoids are CB1, CB2 and TRPV1 receptors as well as MAPK and TIMP-1 pathways. 
However, this does not negate a role for PPAR-γ and COX-2-dependent prostaglandins.  
 
6. Cannabinoids and intestinal cancer 
Endocannabinoid signalling has been proved crucial for certain aspects of gastrointestinal 
homeostasis. It also plays an essential role in the regulation of intestinal tumour growth. Recent 
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studies have demonstrated an up-regulation of anandamide and its metabolite arachidonic acid in 
cancer tissues of patients with colon cancer with lymphatic metastasis (Chen et al., 2015). In 
addition, CB1 receptor expression was elevated (Chen et al., 2015). Another recent study also 
demonstrated that the level of expression of CB2 receptors correlates with cancer progression and 
can predict patient survival in colon cancer patients. Such studies showed that high levels of CB2 
receptors correlate with poor prognosis in patients with tumours in advanced stages or with vascular 
invasion (Martinez-Martinez et al., 2015).  
There are however several controversies regarding the role of the cannabinoid receptors in 
colorectal cancer (Izzo et al., 2009). In adenomatous polyposis coli (APC) gene knock-out models 
(mutation of the gene leads to colon cancer), mice with an additional deletion in the cannabinoid 
receptor 1 (CNR1) gene or subjected to pharmacological blockade of the CB1 receptor, 
demonstrated a higher colonic tumour burden than their littermates whereas activation of CB1 
attenuated intestinal tumor growth by inducing cell death via down-regulation of the anti-apoptotic 
factor survivin (Wang et al., 2008). In contrast to these findings, the CB1 antagonist rimonabant 
inhibited the growth of cancer cells and the development of precancerous lesions in mice (Santoro 
et al., 2009). Other studies showed that non-selective cannabinoid receptor agonists such as 
anandamide, 2-AG and HU-210, and an inhibitor of anandamide inactivation, potently inhibited 
human epithelial colorectal adenocarcinoma cells (CaCo-2 cell) proliferation (Ligresti et al., 2003). 
This effect was less prominent in a less aggressive human colon carcinoma cell line (DLD-1 cells). 
The cell proliferation effect afforded by HU-210 was inhibited by the CB1 and CB2 receptor 
antagonists, rimonabant and SR144528 respectively, only in DLD-1 cells and not in CaCo-2 cells. 
This suggested the involvement of both CB1 and CB2 receptors in mediating an inhibition of cell 
growth (Ligresti et al., 2003). The differential effects observed in the two different cell lines might 
be due to differences in the level of cannabinoid receptor expression. Indeed, it was noted that 
CaCo-2 cells express CB1 receptors but not CB2 receptors and DLD-1 cells express both CB1 and 
CB2 receptors, with CB1 receptor less expressed than in CaCo-2 cells. Later studies suggested that 
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cells with high expression of cyclooxygenase-2 (COX-2) might be a target for the inhibitory action 
of anandamide on cell death in colorectal carcinoma cells (Patsos et al., 2005). Indeed CB2 receptor 
expression has been reported in human adenomatous polyps and carcinomas and in human colonic 
epithelial cell lines (Greenhough et al., 2007; Ihenetu et al., 2003; Ligresti et al., 2003; Wright et al., 
2005). Interestingly the normal epithelial cells do not express CB2 receptors (Wright et al., 2005). 
This suggests that the CB2 receptors are inducible in inflamed tissues or tumour cells. This 
suggestion is in line with other studies which reported an increase in the level of CB2 receptor 
expression associated with increased differentiation,  proliferation, disease and malignancy 
(Fernandez-Ruiz et al., 2007; Mallat et al., 2008). Ceramide synthesis following an increase in the 
level of tumour necrosis factor (TNF)-α and activation of epidermal growth factor receptor have 
been identified as the possible molecular mechanism following the activation of CB2 receptors in 
colon cancer (Cianchi et al., 2008; Hart et al., 2004). Thus since activation of CB2 receptors seem to 
be beneficial in cancer therapy, further studies are needed to investigate the dual role for CB2 
receptors in intestinal regeneration and anti-tumour activity. It is also possible that different 
subtypes of CB2 receptors mediate different roles, however no evidence has yet been reported.  
Cannabinoids have been also reported to exert chemopreventive effects in an experimental 
model of colon cancer, an effect associated with down-regulation of phospho-Akt and up-regulation 
of caspase-3 (Aviello et al., 2012). In vitro studies by the same group on colorectal carcinoma cells 
demonstrated that anti-proliferative effects were exerted through multiple mechanisms, including 
involvement of CB1 receptors, TRPV1 and PPAR-γ (Aviello et al., 2012). Moreover, studies by 
Notarnicola and collaborators firstly described the up-regulation of CB1 expression by 17β-estradiol 
as a further mechanism by which estrogens control colon cancer cell proliferation (Notarnicola et 
al., 2008). Proto and colleagues confirmed these findings and reported an interaction between the 
endocannabinoid system and steroid hormones in the growth of colon cancer cells. Such studies 
revealed that both anandamide and 17β-estradiol inhibited proliferation of human colorectal cancer 
cell lines, SW620 and DLD-1 via interaction with CB1 receptors. Both agonists increased the CB1 
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receptor expression in both cell lines by acting at the same CNR1 gene. Interestingly the up-
regulation of CB1 receptors induced by anandamide analogue was through PPAR-γ and RXRα, 
(Proto et al., 2012). The data suggested that CB1 receptor is a target for 17β-estradiol and that the 
endocannabinoid system could present a tool to improve treatment in patients with colorectal 
cancer.  
 
7. Cannabinoids and reproductive system cancer  
During the last decade, increasing evidence has pointed towards the relevance of 
endocannabinoids in both female and male fertility. This association has been supported by the 
tightly modulated expression of cannabinoid receptor found in gonadal tissues. Along the male 
reproductive tract, CB receptors have been detected in the testis, Sertoli cells, prostate and vas 
deferens (Gye et al., 2005; Maccarrone et al., 2003; Pertwee et al., 2002; Rossato et al., 2005). CB 
receptors have also been found in various parts of the mammalian female reproductive system. In 
the mouse reproductive tract, CB receptors were expressed in the uterus, oviduct and also in pre-
implantation embryos (Das et al., 1995; Paria et al., 2001; Wang et al., 2004). Moreover, this 
localization has also been described in the human uterus (Dennedy et al., 2004; Iuvone et al., 2008) 
and placenta during pregnancy (Habayeb et al., 2008; Helliwell et al., 2004; Park et al., 2003).  
   The influence of cannabinoids on the proliferation of human cervical adenocarcinoma cells and on 
macromolecular biosynthetic events associated with the proliferative process were reported in the 
late 1970s when cannabinoids induced growth inhibition of HeLa cells, human cervical cancer cell 
lines (Blevins et al., 1980; Mon et al., 1978). More recently, an up-regulation of both cannabinoid 
receptors in human ovarian cancer cells OVCAR-3 and SKOV-3 compared to normal Chinese 
hamster ovarian (CHO) cells was found. These findings led to the suggestion that these are targets 
for new therapies for ovarian cancer (Afaq et al., 2006). Recently studies also showed that CB1 
receptor levels are also increased and correlate with disease severity in human epithelial ovarian 
tumours and this has been proposed to be an important factor of bad prognosis following surgery in 
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stage IV colorectal cancer (Messalli et al., 2014; Jung et al., 2013). WIN-55,212-2 was shown to 
exert, via CBR dependent manner, a decrease in cell viability, G1 arrest in cell cycle progression, 
induction of apoptosis and down-regulation of the expression of PCNA and VEGF (Afaq et al., 
2006). An abnormal expression of CB2 receptor has also been reported in biopsies of women 
affected by endometrial carcinoma. Interestingly, the up-regulation was only found in transformed 
malignant cells and the staining of CB2 was completely absent in the normal endometrial tissue 
from the same biopsy (Guida et al., 2010). These findings, together with previous evidence that the 
endocannabinoid system controls cell survival/death decisions (Guzman et al., 2002) by inhibiting 
or stimulating cell growth, suggest that CB2 receptors might play an important role in the growth of 
endometrial carcinoma. The study revealed that the complete endogenous machinery for CB2 
activation was altered in endometrial adenocarcinoma, because the levels of 2-AG, the most 
efficacious endogenous CB2 agonist, were elevated, possibly as a result of the decrease in the 
expression of monoglycerol lipase (MAGL) an important enzyme necessary for 2-AG breakdown. 
On the other hand, CB1 receptors and AEA, a more selective endogenous agonist for CB1, as well as 
FAAH, the most important AEA-metabolizing enzyme, although expressed in healthy endometrial 
tissues, remained unchanged after cell transformation (Guida et al., 2010). 
Additional proteins other than cannabinoid receptors have been considered as possible 
targets in reproductive cancers. Multidrug resistance-related protein 1 (MRP1) or ATP-binding 
cassette (ABC) transporter, ABCC1, is a membrane-bound, ubiquitously expressed energy-
dependent efflux transporter. In terms of physiological function, it is involved in transporting a 
range of glutathione, glucuronide, sulfate conjugates and  cancer drugs, including folate based anti-
metabolites, anthracyclines, plant-derived vinca alkaloids and anti-androgens (Cole et al., 1994; 
Flens et al., 1996; Hooijberg et al., 1999; Keppler et al., 1997). Whilst the transportation of 
metabolites by ABCC1 leads to attenuation of the toxicity of such metabolites might be beneficial, 
efflux of cancer drugs would however reduce intracellular concentrations in tumour cells and hence 
induce drug resistance (Karászi et al., 2001; Norris et al., 1996; Wijnholds et al., 2000; Wijnholds et 
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al., 1998). It has been shown that phytocannabinoids are modulators of the ABC transporters, 
ABCG2 and P-glycoprotein (Holland et al., 2007; Zhu et al., 2000). It was also shown in the human 
ovarian carcinoma cell line that cannabinoids such as cannabinol, cannabidiol and Δ9-THC 
increased the intracellular accumulation of two ABCC1 substrates, Fluo3 and the cancer drug, 
vincristine, in 2008/MRP1 cells (the human ABCC1 transduced subline) (Holland et al., 2008). In 
such experiments cannabidiol was shown to be the most potent and Δ9-THC to be the least potent 
cannabinoid. The rank order of potency for ABCC1 inhibition was independent of the substrate 
assayed (Holland et al., 2008).  Further pre-clinical studies are required to establish if inhibition of 
ABC transporters by cannabinoids can alter the disposition and efficacy of therapeutic drugs that 
are substrates for these transporters.  
With regard to the male reproductive system and its physiology, the antagonizing effect of 
cannabinoids can be dated back to 1974 where experimental models in male rats showed depression 
of spermatogenesis (Dixit et al., 1974) and decrease in circulating testosterone levels (Kolodny et 
al., 1974). Endocannabinoids, through interaction with CB1 receptors and synthetic 
endocannabinoid-vanilloid hybrids via stimulation of TRPV1 channels have been shown to inhibit 
nerve growth factor (NGF)-induced proliferation of human prostate PC-3 cells (Melck et al., 2000). 
However, THC was suggested to induce apoptosis of these cells via a receptor-independent 
mechanism (Ruiz et al., 1999), but also increase the production of the pro-proliferative factor, NGF 
(Velasco et al., 2001). Later studies showed an increased expression of both CB1 and CB2 receptors 
in cultured prostate cancer cells when compared with normal prostate cells. Moreover, treatment of 
prostate cancer cells with WIN-55,212-2 resulted in a dose and time dependent decrease in cell 
viability, increased apoptosis along with decrease in androgen receptor protein expression, PSA 
expression, and secreted PSA, suggesting that cannabinoids should be considered as agents for the 
management of prostate cancer (Ruiz-Llorente et al., 2003; Sanchez et al., 2003; Sarfaraz et al., 
2005). It was also found that a high level of CB1 receptor immunoreactivity (CB1IR) in prostate 
cancer tissues is associated with the severity and outcome of the disease (Chung et al., 2009).  
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It was then suggested that the effect of cannabinoids on prostate cancer cells depends on the 
concentration of cannabinoids used and the incubation time. Cannabinoids used at concentrations 
lower than micromolar induced androgen receptor expression whilst at higher concentrations 
induced apoptosis or cell-cycle arrest (Mimeault et al., 2003; Sanchez et al., 2003; Sarfaraz et al., 
2006). It was also shown that CB1 receptor antagonists prevented/blocked the anti-tumour activity 
of agonists whilst a longer incubation time failed to reveal any antagonist effect (Mimeault et al., 
2003; Sarfaraz et al., 2005).  
Other studies have also indicated an important role for CB2 but not CB1 receptors in the anti-
proliferative effect of cannabinoids (Olea-Herrero et al., 2009). Such studies have shown that in PC-
3 cells pre-treated with rimonabant failed to reduce the effect of methanandamide on cell cycle and 
apoptosis. However, pre-treatment with the CB2 receptor antagonist, SR 144528 attenuated the 
number of apoptotic cells and the number of sub-G1 cells induced by methanandamide and 
apoptosis afforded by the CB2 receptor agonist, JWH-015. Furthermore, when CB2 receptor 
expression was significantly reduced by siRNA, apoptosis afforded by JWH-015 was completely 
antagonised thus further indicating an involvement of CB2 receptors in apoptosis (Olea-Herrero et 
al., 2009).  
Recent studies have focused on the role of non-selective, calcium permeable cation channels 
of the transient receptor potential (TRP) channels in prostate cancer initiation and progression. 
Capsaicin, a natural ligand for TRPV1, has been reported to elicit both pro-proliferative and pro-
apoptotic effects on prostate cancer cell lines (Czifra et al., 2009; Malagarie-Cazenave et al., 2009; 
Malagarie-Cazenave et al., 2011; Sánchez et al., 2006; Sanchez et al., 2005; Ziglioli et al., 2009). 
Moreover, it has been suggested that TRP channels of melastatin-type 8 (TRPM8) are over-
expressed in androgen-dependent prostate cancer cell lines in a manner dependent on androgen 
receptor (AR) activation (Bidaux et al., 2007; Bidaux et al., 2005; Henshall et al., 2003; Tsavaler et 
al., 2001; Zhang et al., 2004). Several studies have shown that cannabinoids antagonize TRPM8 
channels and activate and subsequently desensitize TRPV2 and TRPV1 channels (De Petrocellis et 
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al., 2011; De Petrocellis et al., 2008; Qin et al., 2008). Further recent studies showed an inhibition 
of cell viability and induction of apoptosis by cannabinoids when tested in serum protein-deprived 
medium suggesting an intracellular target for the cannabionids (De Petrocellis et al., 2013). 
However, the molecular mechanism of action was demonstrated to be due not uniquely to a direct 
TRPM8 antagonism, but rather to AR down regulation, which in turn can lead to TRPM8 down-
regulation. As it has been suggested that oestrogens are involved in the survival of prostate cells, the 
authors also examined the involvement of those receptors and they found that GPR30, rather than 
oestrogen metabolic enzymes or ERα or ERβ, may be one of the intracellular targets through which 
cannabinoids stimulate the ER branch of the intrinsic pro-apoptotic pathway Δ9-THC (De 
Petrocellis et al., 2013).  
In addition, the expression of a potential cannabinoid receptor, GPR55 has been also shown 
at the mRNA and protein level in both ovarian and prostate cancer cell lines (Pineiro et al., 2011). 
Although the physiological role of this receptor is not fully understood, it is suggested to have 
important roles in regulating proliferation and growth (Pineiro et al., 2011). This novel receptor is 
suggested to be associated with lysophosphatidylinositol (LPI) to induce calcium mobilization and 
activation of Akt and extracellular signal-regulated kinase (ERK)1/2 in ovarian and prostate cell 
lines. Blockade of this receptor might have novel therapeutic potential in managing ovarian and 
prostate cancer. All these findings indicate that cannabinoids can retard proliferation and cause 
apoptosis of PCC via a combination of cellular and molecular mechanisms (cannabinoid receptor-
mediated and/or independent). These studies are encouraging and they support the development of 
clinical studies on these molecules as a therapy for human prostate carcinoma, either as single agent 
or in combination with existing compounds.  
 
8. Conclusion and Future Direction 
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The substantial knowledge of palliative and anti-tumour actions of cannabinoids gained by 
the scientific community in the last few years has raised the profile of these molecules and many are 
promising candidates for cancer treatment. However, the use of cannabinoids in medicine is limited 
by their psychoactive effects, thus cannabinoid-based therapies that are devoid of unwanted side 
effects or with a safe profile/pharmacological window are required. A further aspect which 
complicates the practise of cannabinoid-based therapies is the lack of detailed understanding of 
their mechanisms of action. There is plenty of evidence in literature, mostly of them reported in this 
review, about the ability of cannabinoids to induce different pathways of cell death depending on 
the neoplastic cell type under investigation. On the other hand, the effect of these compounds on 
several distinct hallmarks of cancer rather than on one single process is potentially desirable. Even 
though the resolution of the conflicting evidence around cannabinoid action still remains a high 
research priority, some key points need to be emphasized. Despite a small number of reports that 
state their inefficacy, the vast majority of independent pre-clinical studies report a sustained anti-
tumour activity for cannabinoids. Moreover, an important feature of cannabinoid pharmacology that 
can have important clinical implications is the lack of toxicity frequently reported on non-tumour 
cells. Cannabinoid-based medicines have been already proven to be safe in thousands of patients 
enrolled in clinical trials for cancer patients (Grotenhermen, 2007; Portenoy et al., 2012; Robson, 
2011). This highlights a need for the identification of the molecular mechanisms which confer 
sensitivity to this class of drugs. Another appealing possibility consists of adding to a standard 
therapy a mixture of molecules able to directly or indirectly target the endocannabinoids system in 
order to enhance anti-tumour actions of chemotherapy and attenuate unwanted iatrogenic side 
effects. Indeed it is interesting to note that the administration of THC and CBD enhanced the radio-
therapeutic effect in an orthotopic murine glioma model (Scott et al., 2014). It is proposed that CBD 
could alleviate the THC-induced side effects such as convulsion, dis-coordination, and psychotic 
episodes, thus it was suggested that the administration of CBD in combination with THC may help 
to improve the tolerability to cannabinoids (Pertwee, 2009). Finally, only the improvement of basic 
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research will lead to the identification of the most appropriate patient population for a cannabinoid-
based therapy and will facilitate the acceptance of cannabinoid use in the clinic.                      
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Figure 1. Chemical structures of some cannabinoids. 
 
Table 1. Tumours, which are sensitive to cannabinoid-induced growth inhibition. 
 
 
Figure 2- Schematic representation showing some examples of pathways activated following the 
activation of cannabinoid receptors. 
 
 
Figure 3. Schematic representation of examples of different pathways associated with anti-
proliferative effects induced by cannabinoid receptor activation in breast cancer.  
 
 
     
     
     
     
     
     
     
     
     
     
 
